Surgical Science Sweden AB (SUS) — Cash Flow-to-Debt Ratio
Surgical Science Sweden AB (SUS) has a Cash Flow-to-Debt Ratio of 0.17x as of December 2025, meaning its operating cash flow of Skr72.89 Million could theoretically repay 0% of its total liabilities (Skr418.31 Million) in one year. See Surgical Science Sweden AB (SUS) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Surgical Science Sweden AB Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Surgical Science Sweden AB across 11 annual periods. Also explore SUS shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Surgical Science Sweden AB (2015–2025)
Year-by-year debt coverage analysis for Surgical Science Sweden AB. For market capitalisation and broader financial context, see Surgical Science Sweden AB stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.19x | Skr79.80 Million | Skr418.31 Million | ▼ -9.5% |
| 2024 | 0.21x | Skr137.22 Million | Skr651.03 Million | ▼ -68.4% |
| 2023 | 0.67x | Skr238.29 Million | Skr357.46 Million | ▲ +112.7% |
| 2022 | 0.31x | Skr129.49 Million | Skr413.11 Million | ▲ +215.2% |
| 2021 | 0.10x | Skr39.08 Million | Skr393.06 Million | ▼ -80.6% |
| 2020 | 0.51x | Skr23.23 Million | Skr45.22 Million | ▼ -49.3% |
| 2019 | 1.01x | Skr55.20 Million | Skr54.54 Million | ▲ +198.4% |
| 2018 | 0.34x | Skr6.88 Million | Skr20.28 Million | ▼ -42.7% |
| 2017 | 0.59x | Skr7.94 Million | Skr13.40 Million | ▲ +82.6% |
| 2016 | 0.32x | Skr13.40 Million | Skr41.30 Million | ▲ +51.8% |
| 2015 | 0.21x | Skr7.50 Million | Skr35.10 Million | — |